PCSK9 inhibitors - clinical applications
The enzyme PCSK9 has an important role in regulating low-density lipoprotein (LDL) receptors and concentrations of LDL cholesterol. Inhibiting this enzyme could therefore reduce the incidence of ischaemic heart disease. The monoclonal antibodies alirocumab, evolocumab and bococizumab are directed against PCSK9 and inhibit its activity. Phase II trials have shown alirocumab and evolocumab to be effective at lowering LDL cholesterol. Preliminary results of these phase II trials show...[Show more]
|Collections||ANU Research Publications|
|01 Schmidli R PCSK9 inhibitors clinical 2016.pdf||200.1 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.